Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

Completed · Phase 1

Conditions studied: Cancer

In brief

RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in treating patients who have advanced cancer.

Key facts

Study ID

NCT00045006

Run by

Memorial Sloan Kettering Cancer Center

Starts

2001-07-01

Expected to finish

2008-07-01

Last updated by the study team

2013-05-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.